Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Diavita Therapeutics LLC currently has 1 pending office action within the Chemistry & Materials technology area. This single active matter is being examined within 1 distinct art unit, reflecting a focused and specific technical engagement with the USPTO. The company's current prosecution efforts are concentrated in this one area of chemistry, rather than being spread across multiple disciplines. The 1 distinct art units involved provide a stable and specialized environment for the review of the company's innovations.
The prosecution is handled by 1 distinct examiners, with TRAN, LIEN THUY serving as the busiest examiner. TRAN, LIEN THUY is responsible for 1 busiest examiner pending office action, which constitutes the total active workload for the portfolio. This one to one relationship between the 1 pending office action and the examiner allows for a very direct and focused communication strategy. For practitioners, the presence of 1 distinct examiners means that the immediate success of the portfolio depends on a single examination process.
There is no need to manage multiple art unit standards or different examiner preferences across this portfolio. The focus remains entirely on the 1 distinct art units involved and the specific feedback provided by TRAN, LIEN THUY in the Chemistry & Materials sector. With 1 busiest examiner pending, the applicant can expect a consistent application of examination guidelines. This concentration in a single technical area highlights the company's primary research focus, while the 1 distinct examiners assigned simplifies the overall management of the prosecution cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, LIEN THUY | 1 | 28.7% | +26.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18781489 | Methods and Compositions for Managing Blood Glucose Levels Using Rare Sugars | TRAN, LIEN THUY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18781489 | Methods and Compositions for Managing Blood Glucose Levels Using Rare Sugars | TRAN, LIEN THUY | — |
| Art Unit | Apps |
|---|---|
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18781489 | Methods and Compositions for Managing Blood Glucose Levels Using Rare Sugars | TRAN, LIEN THUY | 1793 | §103 | Non-Final OA | — | Pending | Jul 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDiavita Therapeutics LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Lien Thuy Tran has the most, with 1 of Diavita Therapeutics LLC's pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.